on Thursday, October 25, 2012
Organizers expect this year to be the most successful yet for this national indoor team cycling event, which raises funds for rare cancer research at Memorial Sloan Kettering.
Cycle for Survival 2013 is expected to be the largest event yet, taking place in ten locations in eight states. Four cities, including Boston and Miami, have been added to the roster of cities, which began with New York and now extends from coast to coast.
More than 13,000 cyclers are expected to join Cycle for Survival in the coming months to raise critical funds for clinical trials and research studies aimed at discovering new treatment options and providing hope for the millions touched by rare cancers around the world.
Cycle for Survival was co-founded in 2007 by Jennifer and David Linn after Jennifer was diagnosed with a rare cancer. It became an official Memorial Sloan Kettering Cancer Center event in 2009. Cycle for Survival has nearly doubled in size and fund-raising totals each year, with all funds directed toward rare cancer research within six months of each ride.
Although more than half of people diagnosed with cancer have a rare form of the disease, research on many rare cancers is underfunded, leaving patients with limited treatment options. Memorial Sloan Kettering is committed to increasing the focus on rare cancers.
Over the past five years, funds raised by Cycle for Survival events have contributed to numerous research studies and discoveries on topics including:
- Glioblastoma multiforme, a primary brain tumor found in adults, which does not respond to many current treatments. Projects funded by Cycle for Survival are determining how tumor cells in the brain modify neighboring connective tissue cells, known as stromal cells, during the development and progression of glioblastomas. This information is vital to generating new, more-effective therapies.
- Diffuse large B-cell lymphoma (DLBCL), an aggressive form of non-Hodgkin lymphoma. A phase I study funded by Cycle for Survival will evaluate the safety of transferring genetically engineered immune cells that target cancer into patients with DLBCL.
- A new project in Memorial Sloan Kettering’s Human Oncology and Pathogenesis Program involving complete DNA studies of patients enrolled in phase I/II clinical trials who are responding to treatment. The goal is to ensure that studies of treatments that have profound, life-altering activity in only a minority of patients are continued in the subset of patients most likely to benefit. These efforts will accelerate the shift toward individually tailored, genetically based cancer treatments.
To learn more, register to ride, or donate, visit Cycle for Survival and join the battle against rare cancers.